Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
10 Demonstrated Tips to Expand Your New Android Cell phone: A Thorough Aide - 2Scientists sent a menstrual cup to space. This is how it went
- 3Doctors seek to understand why quitting antidepressants causes withdrawal for some
- 4He walked on the moon in 1972. This is his advice for the Artemis II astronauts.
- 5Careful Nurturing: Techniques for Bringing up Tough Children
- Voting begins in Uganda’s presidential election during internet shutdown and polling station delays
- Ethiopian earthquakes and volcanic eruptions: earth scientist explains the link
- Consume Fat Quick: 10 Demonstrated Activities for Ideal Outcomes
- How Trump's marijuana executive order could change medical research landscape
- Cocaine, caffeine, painkillers consumed by sharks in Bahamas, study finds
- UK can legally stop shadow fleet tankers, ministers believe
- Europe: 4 Urban communities for a Paramount Social Experience
- From Novice to Master: Dominating a Side interest
- She's been a Bond girl and a mutant. Now she's grappling with Hollywood's obsession with 'eternal youth.'
